CIK 0000906709
- Non-accelerated filer
- Smaller reporting company
NEKTAR THERAPEUTICS
Sign in to watch- Ticker
- NKTR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 943134940
- Phone
- +1 415-482-5300
- Business address
- 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158
- Former names
- INHALE THERAPEUTIC SYSTEMS INC, INHALE THERAPEUTIC SYSTEMS
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-04-09 | Hora Maninder SVP Pharma Dev & Mfg Ops | Exercise or conversion | +9,498 | $7.21 | $68K | 89,759 |
| 2018-04-09 | Hora Maninder SVP Pharma Dev & Mfg Ops | Sale | −9,498 | $105.05 | $998K | 80,261 |
| 2018-04-09 | Hora Maninder SVP Pharma Dev & Mfg Ops | Exercise or conversion · Stock Option | −9,498 | 33,002 | ||
| 2018-04-09 | Doberstein Stephen K SVP & Chief Scientific Officer | Exercise or conversion | +49,500 | $7.21 | $357K | 116,894 |
| 2018-04-09 | Doberstein Stephen K SVP & Chief Scientific Officer | Sale | −49,500 | $96.13 | $4.8M | 67,394 |
| 2018-04-09 | Doberstein Stephen K SVP & Chief Scientific Officer | Exercise or conversion · Stock Option | −49,500 | 0 | ||
| 2018-04-06 | GREER R SCOTT Director | Exercise or conversion | +30,000 | $14.26 | $428K | 160,333 |
| 2018-04-06 | GREER R SCOTT Director | Sale | −30,000 | $92.22 | $2.8M | 130,333 |
| 2018-04-06 | GREER R SCOTT Director | Exercise or conversion · Stock Option | −30,000 | 0 | ||
| 2018-04-06 | Doberstein Stephen K SVP & Chief Scientific Officer | Exercise or conversion | +60,000 | $10.69 | $641K | 127,394 |
| 2018-04-06 | Doberstein Stephen K SVP & Chief Scientific Officer | Exercise or conversion | +50,000 | $7.21 | $361K | 177,394 |
| 2018-04-06 | Doberstein Stephen K SVP & Chief Scientific Officer | Exercise or conversion | +500 | $7.21 | $4K | 177,894 |
| 2018-04-06 | Doberstein Stephen K SVP & Chief Scientific Officer | Sale | −110,500 | $91.69 | $10.1M | 67,394 |
| 2018-04-06 | Doberstein Stephen K SVP & Chief Scientific Officer | Exercise or conversion · Stock Option | −60,000 | 0 | ||
| 2018-04-06 | Doberstein Stephen K SVP & Chief Scientific Officer | Exercise or conversion · Stock Option | −50,000 | 0 | ||
| 2018-04-06 | Doberstein Stephen K SVP & Chief Scientific Officer | Exercise or conversion · Stock Option | −500 | 49,500 | ||
| 2018-04-06 | CHESS ROBERT Director | Exercise or conversion | +10,000 | $14.26 | $143K | 284,223 |
| 2018-04-06 | CHESS ROBERT Director | Sale | −10,000 | $92.15 | $922K | 274,223 |
| 2018-04-06 | CHESS ROBERT Director | Exercise or conversion | +15,000 | $5.14 | $77K | 289,223 |
| 2018-04-06 | CHESS ROBERT Director | Sale | −15,000 | $92.14 | $1.4M | 274,223 |
Page 34 of 43 · 847 trades